An Integrative Approach to Identify Vulnerabilities in Pediatric Cancer DSRCT
An Integrative Approach to Identify Vulnerabilities in Pediatric Cancer DSRCT
批准号:
10360445
负责人:
Sean B. Lee
金额:
$30.37万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-02-01 至 2025-01-31
关键词:
B-LymphocytesBiological ModelsCell SurvivalCellsChemotherapy and/or radiationChromosomal translocationDataData SetDependenceDesmoplastic Small Round Cell TumorDevelopmentEWS-FLI1 fusion proteinEventEwings sarcomaGene ExpressionGene Expression ProfilingGene FamilyGene FusionGenesGoalsIn VitroLeadMalignant Childhood NeoplasmMalignant NeoplasmsMusNTRK3 geneOncogenicOntologyPathway interactionsPatientsPharmaceutical PreparationsPhosphotransferasesPopulationPrognosisProliferatingRadiation therapyRadiosurgeryRecurrenceRecurrent tumorRelapseResistanceRoleSamplingSeedsWT1 geneXenograft Modelbasecancer typecell growthcell typechemotherapychildhood sarcomain vivoinhibitorintraperitonealmortalityneoplastic cellnew therapeutic targetnovelresponsesarcomasmall hairpin RNAstandard carestem cell genestargeted treatmenttranscription factortranscriptome sequencingtumortumor growthtumorigenesistumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Desmoplastic Small Round Cell Tumor (DSRCT) is defined by a recurrent chromosomal translocation that
creates a chimeric transcription factor, EWS-WT1, which is the only known oncogenic driver of DSRCT.
Unfortunately, oncogenic transcription factors such as EWS-WT1 are difficult to target for therapy. Given
that standard treatments are not very effective for DSRCT (less than15% 5 year survival), development of
rationale-based targeted therapy is urgently needed. To do so, new vulnerable oncogenic targets
downstream of EWS-WT1 must be identified. Unfortunately, not much is known about the potential
vulnerable targets in DSRCT. To identify the vulnerabilities in DSRCT, we performed integrative gene
expression analysis using expression profiles of EWS-WT1-depleted DSRCT cells and 28 primary DSRCT
samples. This analysis identified several kinases that could be critical for DSRCT cell growth and survival.
Most cancers contain a small population of tumor initiating cells (TICs) that are thought to serve as seeds
for recurrent tumor growth, but TICs have not yet been identified in DSRCT. We have recently identified a
novel culture condition that produces spheroids in DSRCT which display significantly higher tumor-seeding
activity than the adherent cells. Deep RNA sequencing analysis of spheroids has revealed a number of
kinases that are enriched in spheroids. Thus, the goal of this proposal is to identify key vulnerabilities in
DSRCT that will ultimately lead to development of rationale-based targeted therapy.
Aim 1. Investigate the identified kinases as potential vulnerabilities in DSRCT. We have identified NTRK3,
ROCK2 and SIK1 kinases that are highly expressed in primary DSRCT tumors and in DSRCT cells. We will
investigate the effects of inhibiting these kinases on DSRCT cell growth in vitro and in vivo.
Aim 2. Investigate the roles of BLK, NTRK3 and ROCK2 in spheroids. Our deep RNA sequencing analysis
of highly tumorigenic spheroids has revealed a number of kinases whose expression is greatly increased in
spheroids. We will investigate the effects of inhibiting these kinases in tumorigenic capacity of spheroids
using our orthotopic intraperitoneal DSRCT xenograft model.
DSRCT remains untreatable with unacceptably high mortality. Our integrative gene expression analysis
and our recent discovery of spheroids in DSRCT have revealed several kinases that could be critical for
DSRCT growth or survival. These complementary approaches will ultimately lead to development of
durable targeted therapies in DSRCT. Our integrative approach in identifying vulnerable targets could be
applied to finding critical dependencies in other related pediatric sarcomas such as Ewing sarcoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An Integrative Approach to Identify Vulnerabilities in Pediatric Cancer DSRCT
-
批准号:10553217
-
项目类别:
-
资助金额:$30.37万
-
财政年份:2019
-
负责人:Sean B. Lee
-
依托单位:
An Integrative Approach to Identify Vulnerabilities in Pediatric Cancer DSRCT
-
批准号:10092975
-
项目类别:
-
资助金额:$19.61万
-
财政年份:2019
-
负责人:Sean B. Lee
-
依托单位:
Desmoplastic Small Round Cell Tumor/Ewings Sarcoma Model
-
批准号:7153399
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
Characterization Of Wilms Tumor Suppressor Gene Product
-
批准号:6659567
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
Characterization Of Wilms Tumor Suppressor Gene Product
-
批准号:6810539
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
Mouse models of Desmoplastic Small Round Cell Tumor and Ewings sarcoma
-
批准号:7734222
-
项目类别:
-
资助金额:$40.74万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
Characterization Of Wilms Tumor Suppressor Gene Product
-
批准号:6984023
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
Characterization Of Wilms Tumor Suppressor Gene Product
-
批准号:7153397
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
Characterization Of Wilms Tumor Suppressor Gene Product
-
批准号:7337558
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
Characterization Of Wilms Tumor Suppressor Gene Product Wt1
-
批准号:7734221
-
项目类别:
-
资助金额:$34.92万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
Characterization Of Wilms Tumor Suppressor Gene Product Wt1
-
批准号:7593696
-
项目类别:
-
资助金额:$35.41万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
Mouse models of Desmoplastic Small Round Cell Tumor and
-
批准号:7337600
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
Mouse models of Desmoplastic Small Round Cell Tumor and Ewings sarcoma
-
批准号:7593697
-
项目类别:
-
资助金额:$41.32万
-
财政年份:--
-
负责人:Sean B. Lee
-
依托单位:
海外基金